Skip to main content
    B

    Beam Therapeutics Inc (BEAM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $20.94
    -1.89 (-8.28%)

    Market Cap: $2.36B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Beam Therapeutics Inc (BEAM) Earnings: Report Dates and Results

    Updated Nov 3, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Beam Therapeutics (BEAM) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Beam Therapeutics reported EPS of -$1.28, below the -$1.17 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    50%(14/28)
    Avg Surprise
    -35.21%

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$1.25
    Range-$1.32 - -$1.19
    17 analysts
    Revenue Consensus
    $6.30M
    RangeN/A
    16 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$1.24
    Range-$1.25 - -$1.23
    2 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$1.20-3.8%
    60d ago-$1.20-3.8%
    30d ago-$1.20-3.8%
    7d ago-$1.21-2.5%
    Current-$1.24
    Revenue Consensus
    $400.00K
    Range$300.00K - $500.00K
    2 analysts

    Next Report

    BEAM has an expected report date of Feb 22, 2027.

    BEAM Earnings Call

    The latest BEAM earnings call transcript on file is labeled 2025Q4.

    Read the 2025Q4 transcript

    Earnings History

    Of the 28 quarters below that had an estimate, BEAM beat 14, missed 13 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $307000, down 96.8% from $9.70M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.28-$1.17-$1.28 - -$1.05-9.40%MissN/A134 up, 5 downNov 3, 2026$307000
    Jun 30, 2026-$1.18$1.00N/A-218.00%MissN/A122 up, 8 downAug 4, 2026$490000
    Mar 31, 2026-$0.91-$1.01-$1.19 - -$0.08+9.90%BeatN/A136 up, 1 downMay 7, 2026$31.74M
    Dec 31, 2025$2.33-$1.01-$1.28 - -$0.90+330.69%BeatN/A131 up, 7 downFeb 24, 2026$114.11M
    Sep 30, 2025-$1.10-$1.01-$1.16 - -$0.79-8.91%MissN/A120 up, 0 downNov 4, 2025$9.70M
    Jun 30, 2025-$1.00-$1.09-$1.40 - -$0.78+8.26%BeatN/A140 up, 1 downAug 5, 2025$8.47M
    Mar 31, 2025-$1.24-$1.17-$1.47 - -$0.70-5.98%MissN/A141 up, 4 downMay 6, 2025$7.47M
    Dec 31, 2024-$1.09-$1.22-$1.59 - -$0.88+10.35%Beat-163.0%162 up, 0 downFeb 25, 2025$30.07M
    Sep 30, 2024-$1.17-$1.18-$1.35 - -$0.94+0.85%BeatN/A160 up, 0 downNov 5, 2024$14.27M
    Jun 30, 2024-$1.11-$1.12-$1.33 - -$0.91+0.89%BeatN/A140 up, 0 downAug 6, 2024$11.77M
    Mar 31, 2024-$1.21-$1.39-$2.16 - -$1.18+12.95%BeatN/A120 up, 0 downMay 7, 2024$7.41M
    Dec 31, 2023$1.73-$1.01-$1.46 - $1.21+271.29%BeatN/A121 up, 0 downFeb 27, 2024$316.19M
    Sep 30, 2023-$1.22-$1.27-$1.62 - -$1.19+3.94%BeatN/A131 up, 1 downNov 8, 2023$17.19M
    Jun 30, 2023-$1.08-$1.38-$1.73 - -$1.15+21.74%BeatN/A130 up, 0 downAug 8, 2023$20.12M
    Mar 31, 2023-$1.33-$1.30-$1.61 - -$1.12-2.31%MissN/A130 up, 0 downMay 10, 2023$24.21M
    Dec 31, 2022-$0.54-$1.33-$1.85 - -$0.79+59.40%BeatN/A140 up, 0 downFeb 28, 2023$20.04M
    Sep 30, 2022-$1.56-$1.09N/A-43.12%MissN/A120 up, 0 downNov 7, 2022$15.80M
    Jun 30, 2022-$1.02-$1.02-$1.28 - -$0.850.00%In lineN/A110 up, 0 downAug 9, 2022$16.65M
    Mar 31, 2022-$1.01-$1.34N/A+24.63%BeatN/AN/AN/AMay 9, 2022$8.43M
    Dec 31, 2021-$0.95-$1.03N/A+7.77%BeatN/AN/AN/AFeb 28, 2022$51.07M
    Sep 30, 2021-$0.42-$0.72N/A+41.67%BeatN/AN/AN/ANov 8, 2021$763000
    Jun 30, 2021-$1.23-$0.74N/A-66.22%MissN/AN/AN/AAug 10, 2021$6000
    Mar 31, 2021-$3.35-$0.75N/A-346.67%MissN/AN/AN/AMay 11, 2021$6000
    Dec 31, 2020-$1.69-$0.67N/A-152.24%MissN/AN/AN/AMar 15, 2021$6000
    Sep 30, 2020-$0.69-$0.54N/A-27.78%MissN/AN/AN/ANov 10, 2020$6000
    Jun 30, 2020-$0.69-$0.51N/A-35.29%MissN/AN/AN/AAug 12, 2020$6000
    Mar 31, 2020-$1.03-$0.48N/A-114.58%MissN/AN/AN/AMay 12, 2020$6000
    Dec 31, 2019-$4.47-$0.52N/A-759.62%MissN/AN/AN/AFeb 7, 2020$6000
    Sep 30, 2019-$1.44N/AN/AN/AN/AN/AN/AN/ANov 27, 2019$6000
    Jun 30, 2019-$0.45N/AN/AN/AN/AN/AN/AN/ASep 27, 2019$6000
    Last 30 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.01, after -$4.58 the year before. It was -$6.36 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.01N/A
    Dec 31, 2024-$4.58N/A
    Dec 31, 2023-$1.90N/A
    Dec 31, 2022-$4.13N/A
    Dec 31, 2021-$5.95N/A
    Dec 31, 2020-$4.10N/A
    Dec 31, 2019-$6.36N/A

    Earnings Calls

    The 2 most recent earnings calls are listed below; the latest, 2025Q4 for the period ended Dec 31, 2025, runs about 9,300 words across 21 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q4Dec 31, 20259,33121
    2024Q3Sep 30, 20245,77916

    2025Q4 Earnings Call

    Opening remarks

    Holly Manning Vice President of Investor Relations and External Communications Thank you, operator. Good morning, everyone, and welcome to Beam's Conference Call to review updates announced this morning in conjunction with our fourth quarter and year-end 2025 financial results. You can access slides for today's call by going to the Investors section of our website, beamtx.com. With me on the call today, with prepared remarks, are John Evans, our Chief Executive Officer; Dr. Amy Simon, our Chief Medical Officer; Dr. Gopi Shanker, our Chief Scientific Officer; Sravan Emany, our Chief Financial Officer; and Dr. Kiran Musunuru from the University of Pennsylvania. Our President, Dr. Guiseppe Pino Ciaramella, will join for Q&A. Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the Risk Factors section of our most recent annual report on Form 10-K and any other filings that we may make with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as required by law, Beam specifically disclaims any obligation to update or revise any forward-looking statements even if our views change. With that, I'll turn the call over to John.

    John Evans CEO Thanks, Holly, and good morning, everyone. At Beam, our vision is straightforward, but ambitious: to provide lifelong cures for patients suffering from serious diseases. We believe base editing has the potential to deliver on that vision through onetime durable genetic medicines with predictable and reproducible outcomes. Today, we're excited to share several important updates that bring us closer to accomplishing this mission. First, leveraging our platform to bring forward a new and innovative development program to address a serious genetic disease, phenylketonuria, or PKU, and second, further solidifying our balance sheet to support the anticipated commercialization of a potentially transformative onetime base editing therapy for sickle cell disease. Beam was founded on a simple concept: aimed at rewriting broken genes back to normal. Base editing is a next-generation form of CRISPR that allows us to make precise single-base changes, resulting in predictable edits without the need to make double-stranded breaks in DNA. With consistent gene sequence outcomes conferring potentially lifelong benefit, base editing enables predictable, reproducible outcomes for patients. This scientific foundation underpins everything we do. Predictability is a theme you'll hear throughout today's discussion.

    Frequently Asked Questions About BEAM

    When is Beam Therapeutics's next earnings date?

    Beam Therapeutics's next earnings report is expected for Feb 22, 2027.

    Did BEAM beat earnings estimates last quarter?

    No. Beam Therapeutics reported EPS of -$1.28 for the quarter ended Sep 30, 2026, below the -$1.17 estimate by 9.40%.

    What EPS do analysts expect from BEAM next quarter?

    The consensus EPS estimate for Beam Therapeutics for the quarter ending Dec 31, 2026 is -$1.25 from 17 analysts, with estimates from -$1.32 to -$1.19.

    How often does BEAM beat earnings estimates?

    Beam Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +14.61%.